The Schroders Capital Innovation trust, previously the Woodford Patient Capital trust managed by former star fund manager Neil Woodford, is facing uncertainty over its future after the company's board brought forward its continuation vote.
According to a London Stock Exchange notice issued today (6 December), the board determined that, following shareholder consultation, the continuation vote scheduled for May 2025 should be moved up to "provide clarity on the future of the company at the earliest opportunity". It did not however provide a new date or timeline for this to occur. Schroders Capital Global Innovation slashes stake in underperforming legacy holding Oxford Nanopore Until the outcome of the continuation vote is settled, the trust has committed to making no further new investments, although further investme...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
